Immunomedics INC (IMMU) Shareholder Sphera Funds Management LTD Lowered Position

May 26, 2018 - By Kurt Siggers

Immunomedics, Inc. (NASDAQ:IMMU) LogoInvestors sentiment decreased to 1.07 in 2017 Q4. Its down 0.58, from 1.65 in 2017Q3. It dived, as 27 investors sold IMMU shares while 44 reduced holdings. 29 funds opened positions while 47 raised stakes. 117.18 million shares or 4.91% more from 111.69 million shares in 2017Q3 were reported. 1.62 million are owned by Pictet Asset Mgmt. Invesco Ltd accumulated 548,943 shares or 0% of the stock. Chicago Equity Prns Limited Liability reported 43,350 shares. Citigroup owns 489,831 shares. D E Shaw & Company owns 43,391 shares. Teacher Retirement System Of Texas holds 0% or 32,436 shares. Amalgamated Bankshares reported 13,749 shares or 0.01% of all its holdings. Nea Mgmt Limited, a Maryland-based fund reported 2.77 million shares. Next Group Inc Incorporated holds 0.84% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 121,350 shares. 4.77M are owned by Palo Alto Invsts Ltd. Metropolitan Life Insur New York has 34,221 shares. Bank Of Mellon stated it has 0% in Immunomedics, Inc. (NASDAQ:IMMU). Great West Life Assurance Can holds 21,882 shares or 0% of its portfolio. Proshare Advsrs Ltd Com holds 0.01% in Immunomedics, Inc. (NASDAQ:IMMU) or 97,075 shares. Lyon Street Cap Ltd Limited Liability Company holds 2.41% or 446,703 shares in its portfolio.

Since February 28, 2018, it had 0 insider purchases, and 1 insider sale for $2.05 million activity.

Sphera Funds Management Ltd decreased its stake in Immunomedics Inc (IMMU) by 48.89% based on its latest 2017Q4 regulatory filing with the SEC. Sphera Funds Management Ltd sold 220,000 shares as the company’s stock rose 3.28% while stock markets declined. The institutional investor held 230,000 shares of the health care company at the end of 2017Q4, valued at $3.72 million, down from 450,000 at the end of the previous reported quarter. Sphera Funds Management Ltd who had been investing in Immunomedics Inc for a number of months, seems to be less bullish one the $3.81B market cap company. The stock increased 0.89% or $0.2 during the last trading session, reaching $22.78. About 1.42 million shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 117.70% since May 26, 2017 and is uptrending. It has outperformed by 106.15% the S&P500.

Sphera Funds Management Ltd, which manages about $852.23M US Long portfolio, upped its stake in Viking Therapeutics Inc by 1.86M shares to 2.15M shares, valued at $8.71 million in 2017Q4, according to the filing. It also increased its holding in Vertex Pharmaceuticals Inc (NASDAQ:VRTX) by 65,000 shares in the quarter, for a total of 85,823 shares, and has risen its stake in Prothena Corp Plc (NASDAQ:PRTA).

Analysts await Immunomedics, Inc. (NASDAQ:IMMU) to report earnings on August, 15. They expect $-0.15 EPS, up 40.00 % or $0.10 from last year’s $-0.25 per share. After $-0.14 actual EPS reported by Immunomedics, Inc. for the previous quarter, Wall Street now forecasts 7.14 % negative EPS growth.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Immunomedics had 3 analyst reports since December 6, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, December 6 by Cowen & Co. Jefferies maintained the stock with “Buy” rating in Wednesday, December 6 report. The rating was maintained by Wells Fargo on Thursday, May 17 with “Buy”.

Immunomedics, Inc. (NASDAQ:IMMU) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.